Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Needham › NPI 1205893450
Hospital

Beth Israel Deaconess Hospital-Needham, INC.

Beth Israel Deaconess Hospital-Needham, INC. was paid $12.41M by Medicaid between Jan 2018 and Dec 2024, across 216 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.

33Billing provider infoBETH ISRAEL DEACONESS HOSPITAL-NEEDHAM, INC.
NEEDHAM, MA 02492
33aNPI1205893450assigned 04/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.41M
24GClaims456,902
24DCodes billed216
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#41 of 66
Median peer was paid$29.11M
This provider vs. median0.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201847,079$1.27M
201951,761$1.23M
202046,696$1.17M
202180,456$1.98M
202278,543$2.19M
202383,412$2.45M
2024incomplete68,955$2.11M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 14% 12,237 11,114 $1.75M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 9.6% 7,884 7,246 $1.20M
96361 Intravenous infusion, hydration; each additional hour 8.1% 2,998 2,742 $1.01M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 6.6% 5,896 5,512 $814K
95810 Polysomnography; sleep staging with 4 or more additional parameters 6.4% 1,054 1,036 $797K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 6.2% 5,851 5,494 $770K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5.8% 4,933 4,591 $716K
95811 4.8% 873 840 $592K
G0378 Hospital observation service, per hour 3.0% 2,211 1,984 $369K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 2.9% 15,566 13,392 $362K
74177 Computed tomography, abdomen and pelvis; with contrast material 2.1% 2,881 2,718 $259K
S9485 Crisis intervention mental health services, per diem 1.9% 820 567 $240K
204 more codes
77063 Screening digital breast tomosynthesis, bilateral 1.6% 2,481 $199K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.6% 3,785 $198K
45380 Colonoscopy, flexible; with biopsy, single or multiple 1.6% 195 $193K
70450 Computed tomography, head or brain; without contrast material 1.3% 2,583 $163K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 1.2% 4,635 $146K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 1,590 $119K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 1,772 $119K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 6,434 $105K
80053 Comprehensive metabolic panel <1% 23,985 $101K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 26,496 $97K
84443 Thyroid stimulating hormone (TSH) <1% 11,950 $95K
83036 Hemoglobin; glycosylated (A1C) <1% 13,742 $84K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 2,205 $72K
77067 Screening mammography, bilateral, including computer-aided detection <1% 2,498 $72K
71046 Radiologic examination, chest; 2 views <1% 4,868 $69K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 2,209 $68K
80048 Basic metabolic panel (calcium, ionized) <1% 15,855 $68K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 753 $68K
99215 Doctor's office visit, returning patient (complex) <1% 358 $66K
80061 Lipid panel <1% 18,312 $63K
80050 General health panel <1% 3,448 $60K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 338 $50K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 4,753 $47K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,077 $46K
20610 <1% 270 $44K
86803 <1% 2,635 $42K
82607 <1% 5,770 $41K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 486 $38K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 49 $37K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 1,890 $34K
84153 <1% 2,278 $33K
84484 <1% 4,696 $31K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 423 $31K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 2,016 $30K
85027 <1% 9,447 $30K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 965 $29K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 1,172 $27K
82728 <1% 3,190 $27K
87086 Culture, bacterial; quantitative colony count, urine <1% 6,975 $26K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 1,165 $26K
83735 <1% 7,510 $25K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 9,573 $23K
ATP14 <1% 5,143 $22K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 151 $22K
76642 <1% 176 $21K
84439 <1% 3,495 $18K
84403 <1% 870 $18K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 112 $17K
83690 <1% 4,203 $17K
71045 Radiologic examination, chest; single view <1% 2,468 $16K
81025 <1% 2,967 $16K
82948 <1% 6,284 $15K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 83 $15K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 12 $13K
71275 Computed tomographic angiography, chest, with contrast material <1% 68 $13K
83540 <1% 3,296 $12K
77080 <1% 179 $12K
87186 <1% 1,866 $12K
82570 <1% 4,228 $11K
81001 <1% 7,743 $11K
83880 <1% 1,328 $11K
86618 <1% 350 $10K
82043 <1% 3,695 $9K
ATP08 <1% 2,884 $8K
82746 <1% 906 $8K
87070 <1% 1,208 $8K
83605 <1% 1,507 $8K
85610 <1% 5,478 $8K
80305 <1% 1,785 $8K
86140 <1% 1,737 $8K
84450 <1% 4,228 $7K
84702 <1% 688 $7K
ATP15 <1% 1,006 $7K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 3,696 $7K
83721 <1% 2,675 $7K
96375 Therapeutic injection; each additional sequential IV push <1% 3,148 $6K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 834 $6K
84460 <1% 4,909 $6K
87631 <1% 78 $6K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,879 $6K
36415 Collection of venous blood by venipuncture <1% 23,932 $6K
82565 <1% 4,585 $6K
87340 <1% 457 $6K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 67 $6K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 4,967 $5K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 24 $5K
81003 <1% 4,385 $5K
86592 <1% 184 $5K
80076 <1% 1,770 $4K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 16 $4K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 35 $4K
86706 <1% 230 $4K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 118 $4K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 26 $4K
84100 <1% 4,220 $4K
83970 <1% 278 $4K
88142 <1% 119 $4K
ATP17 <1% 2,009 $3K
85730 <1% 1,270 $3K
82330 <1% 718 $3K
J2704 Injection, propofol, 10 mg <1% 5,342 $3K
77062 <1% 27 $3K
A9585 Injection, gadobutrol, 0.1 ml <1% 887 $3K
85652 <1% 1,200 $2K
86038 <1% 249 $2K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 2,623 $2K
76775 <1% 20 $2K
82550 <1% 1,899 $2K
80143 <1% 1,306 $2K
73562 <1% 146 $2K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 2,468 $2K
70496 <1% 15 $2K
87205 <1% 395 $2K
71250 <1% 38 $2K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 30 $2K
73130 <1% 72 $2K
81513 <1% 13 $2K
77066 Tomosynthesis, mammo <1% 44 $2K
72125 Computed tomography, cervical spine; without contrast material <1% 699 $1K
84520 <1% 2,874 $1K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 49 $1K
76830 Ultrasound, transvaginal <1% 27 $1K
85014 <1% 1,462 $1K
J2060 Injection, lorazepam, 2 mg <1% 173 $1K
99218 <1% 58 $1K
86703 <1% 85 $1K
71271 <1% 13 $1K
76536 <1% 14 $1K
97803 <1% 12 $1K
86850 <1% 331 $1K
ATP03 <1% 560 $1K
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 429 $967.53
82784 <1% 82 $943.10
82803 <1% 139 $932.80
84302 <1% 591 $908.11
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 237 $902.27
J2270 Injection, morphine sulfate, up to 10 mg <1% 836 $889.25
J1170 Injection, hydromorphone, up to 4 mg <1% 362 $879.43
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 43 $846.67
83516 <1% 25 $797.12
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 15 $769.65
82040 <1% 555 $750.43
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 110 $731.75
85379 <1% 135 $681.53
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,048 $654.02
Q3014 Telehealth originating site facility fee <1% 387 $606.79
85651 <1% 151 $579.23
86900 <1% 363 $575.20
86901 <1% 358 $552.99
87503 <1% 89 $540.08
ATP18 <1% 307 $537.53
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 12 $513.24
94010 <1% 37 $503.49
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 336 $496.09
83718 <1% 177 $450.99
85018 <1% 569 $407.29
73030 <1% 26 $398.71
87481 <1% 13 $371.38
97162 <1% 13 $360.84
82670 <1% 12 $256.86
87102 <1% 17 $222.72
73110 <1% 30 $219.70
J0690 Injection, cefazolin sodium, 500 mg <1% 665 $218.15
87147 <1% 13 $215.57
84075 <1% 224 $203.66
84146 <1% 12 $198.21
87430 <1% 14 $177.96
82947 <1% 24 $161.49
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg <1% 91 $158.89
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 104 $158.89
88304 <1% 27 $154.04
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 4,759 $150.35
84480 <1% 13 $142.34
84550 <1% 95 $140.79
80051 <1% 93 $135.62
ATP11 <1% 42 $118.43
84132 <1% 395 $117.61
86431 <1% 24 $107.66
86141 <1% 14 $107.43
87088 <1% 52 $72.30
87077 <1% 62 $66.33
82247 <1% 12 $64.20
87081 <1% 12 $58.50
87040 <1% 13 $54.60
82310 <1% 165 $51.28
J1030 Injection, methylprednisolone acetate, 40 mg <1% 39 $48.65
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 399 $36.48
82465 <1% 177 $31.96
82374 <1% 127 $29.06
82435 <1% 143 $27.57
84478 <1% 177 $14.04
ATP13 <1% 23 $11.04
83550 <1% 27 $9.02
82962 0% 86 $0.00
96376 0% 62 $0.00
70498 0% 15 $0.00
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 0% 12 $0.00
J3490 Unclassified drugs 0% 16 $0.00
73560 0% 12 $0.00
82248 0% 162 $0.00
73610 0% 14 $0.00
73630 0% 13 $0.00
J1200 Injection, diphenhydramine hcl, up to 50 mg 0% 15 $0.00
J7120 Ringers lactate infusion, up to 1000 cc 0% 14 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHOFFMAN, NANCY (CHIEF FINANCIAL OFFICER)
Same official

Other billing entities under HOFFMAN, NANCY

Full network →
ProviderLocationPaid
The Association for Retarded Citizens of Wabash County, INC.Wabash, IN$4.53M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.